Research & Development

Retrogenix and Resonant Therapeutics announce strategic alliance to identify targets of anti-tumour antibodies

UK-based biotechnology company Retrogenix and US-based Resonant Therapeutics, Inc. announced today that they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.

Sanofi to acquire Synthorx for $2.5bn to strengthen immuno-oncology pipeline

Sanofi has agreed to acquire US-based clinical-stage biotechnology company Synthorx for about $2.5bn in an all-cash deal in a move to strengthen its immuno-oncology (IO) pipeline.

Incheon City envisions biotech Mecca by developing Songdo Global Biotech Cluster

The Incheon Metropolitan City government announced an ambitious plan for developing the Songdo Global Biotech Cluster in the Incheon Free Economic Zone.

Merck to buy biopharmaceutical firm ArQule for $2.7bn

Merck has signed an agreement to acquire biopharmaceutical company ArQule for a total equity value of around $2.7bn.

XBiotech to sell anti- IL-1⍺ antibody bermekimab to Janssen in $1.3bn deal

XBiotech has agreed to offload its human antibody bermekimab to Janssen Biotech, a subsidiary of Janssen Pharmaceutical Company of Johnson & Johnson, in a deal worth up to $1.35bn.

Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments

Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a leading life sciences innovation fund.

Gatehouse Bio collaborates with AstraZeneca to accelerate new drug discovery

Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s Artificial Intelligence (AI)-powered platform.

IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets

IONTAS, a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

Astellas Pharma to buy Audentes Therapeutics for $3bn

Japan-based Astellas Pharma has agreed to acquire AAV-based genetic medicines company Audentes Therapeutics for a total equity value of around $3bn.